Lineage Cell Therapeutics Inc (LCTX)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.08-1.82%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
Broken: Recent financial performance freshly dropped to the bottom half of its industry.
Lineage aims to grow revenue from $1.7M in Q2 to $14.6M in 2026. The company has partnerships with Roche and WDI to develop cell therapies. Management focuses on advancing new treatments and building a pipeline. These steps could help the company become profitable.
Lineage is still losing money and revenue is small. The company missed earnings twice last year. Its therapies are early stage and may not succeed. The stock fell 23% from its high.
The market expects about 15% revenue growth next year. Our fair value is near the current price, reflecting cautious optimism on growth and risks.
Breaks if: No meaningful progress or setbacks in key therapeutic programs
Focus on advancing therapeutic candidates and creating a pipeline of cell-based assets.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This is a speculative growth investment with a focus on advancing therapeutic candidates. The current thesis state has weakened due to recent financial performance dropping significantly within its industry.
The market appears to assume a durable premium for LCTX, despite its loss-making status. There is an expectations gap, suggesting that while the stock is priced with high hopes, the recent performance does not fully justify this valuation.
Management is focused on advancing therapeutic candidates and pursuing partnerships, which may help stabilize revenue. However, the recent financial performance has been weak, and there is elevated risk in the near term due to potential misses.
The long-term thesis hinges on management's ability to execute on their priorities and the overall health of the healthcare sector. Key factors include guidance updates and performance from sector leaders that could influence sentiment.
The most important moves since the prior daily snapshot.
risk label changed from 'high' to 'elevated'.
Yes, our read has weakened. Recent financial performance dropped from the robust to the weak half of its sector. This change indicates a decline in the reasons to own the company. The market reaction has been muted, reflecting uncertainty about its future.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Loss of key partnerships or no new deals in 2026
Maintain and expand collaborations such as with Roche, Genentech, and William Demant Invest A/S to support development and commercialization of cell therapy programs.
Stated as a priority in 2 of last 2 quarters. Revenue grew modestly from $1.5M in 2025-Q1 to $1.7M in 2026-Q1, reflecting collaboration revenue from WDI. Management continues to pursue and maintain partnerships supporting cell-based assets, showing delivering progress.
“Lineage supports Roche and Genentech clinical development of OpRegen and research collaboration with WDI for ReSonance.”
“Research collaboration established with William Demant Invest A/S to advance ReSonance preclinical development.”
Breaks if: Revenue falls below $14 million in FY26
Over the next 1 to 3 years, LCTX's prospects depend on execution and sector dynamics. Not investment advice.